Loading company…
Rondo Therapeutics develops bispecific antibody therapies for cancer, with a focus on solid tumors.
Founded in 2020 and based in California, Rondo Therapeutics develops immuno-oncology therapies using bispecific antibodies designed to engage the immune system and address solid tumors. In March 2022, it raised USD 67 million in Series A funding co-led by Canaan Partners and Red Tree Venture Capital, with Johnson & Johnson Innovation, Novo Holdings, and SV Health Investors participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in